Journal
JOURNAL OF APPLIED TOXICOLOGY
Volume 32, Issue 11, Pages 890-899Publisher
WILEY
DOI: 10.1002/jat.2742
Keywords
silver nanoparticles; acute toxic effects; gender-related biokinetics; tissue distribution; mice
Categories
Funding
- National Key Project on Scientific Research of China [2011CB933404]
- National Natural Science Foundation of China [30972504, 81172697]
- Provincial Natural Science Foundation of Jiangsu [BK2011606]
- Science Foundation of Southeast University [KJ2010440]
Ask authors/readers for more resources
This study evaluated the acute toxicity and biokinetics of intravenously administered silver nanoparticles (AgNPs) in mice. Mice were exposed to different dosages of AgNPs (7.5, 30 or 120?mg kg-1). Toxic effects were assessed via general behavior, serum biochemical parameters and histopathological observation of the mice. Biokinetics and tissue distribution of AgNPs were evaluated at a dose of 120?mg kg-1 in both male and female mice. Inductively coupled plasmamass spectrometry (ICP-MS) was used to determine silver concentrations in blood and tissue samples collected at predetermined time intervals. After 2?weeks, AgNPs exerted no obvious acute toxicity in the mice. However, inflammatory reactions in lung and liver cells were induced in mice treated at the 120?mg kg-1 dose level. The highest silver levels were observed in the spleen, followed by liver, lungs and kidneys. The elimination half-lives and clearance of AgNPs were 15.6?h and 1.0?ml h-1 g-1 for male mice and 29.9?h and 0.8?ml h-1 g-1 for female mice. These results indicated that AgNPs could be distributed extensively to various tissues in the body, but primarily in the spleen and liver. Furthermore, there appears to be gender-related differences in the biokinetic profiles in blood and distribution in lungs and kidneys following an intravenous injection of AgNPs. The data from this study provides information on toxicity and biodistribution of AgNPs following intravenous administration in mice, which represents the worst case scenario of toxicity among all the different administration routes, and may shed light in the future use of products containing AgNPs in humans. Copyright (c) 2012 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available